CUSABIO | 開啟 CAR-T 細胞療法的潛力,全面的解決方案和專業知識

CUSABIO | 開啟 CAR-T 細胞療法的潛力,全面的解決方案和專業知識

2024.09.18

 

Chimeric Antigen Receptor T (CAR-T) cell therapy is a genetic engineering technology that transforms a patient’s own T-cells to express receptors on their surface that can recognize specific antigens of tumor cells. The modified T-cells are thus able to accurately recognize and kill tumor cells, thus achieving the purpose of cancer treatment.

Currently, CAR-T therapy has demonstrated significant efficacy in the treatment of certain types of cancer, such as certain lymphomas and leukemias, and is gradually expanding to solid tumors and autoimmune diseases.

With years of expertise in protein, antibody, and ELISA kit development, CUSABIO possesses an extensive range of research reagents for viral studies and provides high-quality technical services. We are dedicated to supporting various stages of CAR-T cell therapy development, including CAR development, CAR-T preparation, CAR-T cell quality control and preclinical evaluation.

Product

Service

CAR Development

scFv Screening

CAR Candidate Development and Screening

CAR-T Preparation

T Cells Activation

T Cells Expansion

Quality Control

CAR Expression Evaluation

  • Flow Cytometry Antibodies

CAR-T Cell Population Profiling

CAR-T Cells Detection

Preclinical Evaluation

CAR-T Potency and Functionality Test

  • Fiow Cytometry Antibodies

CAR-T cells Monitoring

Residual Tumor Cells Detection

PK, Immunogenicity Analysis

In Vitro CAR-T Cells Potency Evaluation

Kit

Protein

Antibody

Molecular Biology

 

CUSABIO TECHNOLOGY LLC

Postal Address:

7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA

Website: www.cusabio.com

© 2024 CUSABIO All Products For Research Use Only

linkedInFacebookTwitterYoutube

 

back-Top
open-line

LINE 線上諮詢

亞旭-LINE-QRcode

掃瞄或手機直接點擊條碼

error: Content is protected !!